"我们很高兴能够将HiCB平台－公司在高度一体化连续流生物工艺领域的领先成果 － 与志同道合的合 作伙伴分享，共同推动生物药生产的变革"，公司董事会主席兼首席执行官钱雪明博士表示："通过让合 作伙伴应用HiCB平台，我们可以共同推进创新生物药的可负担性和全球可及性。此次及未来合作所产 生的收益，将再度投入于技术平台的强化及研发管线的推进，致力于开发下一代、同类最佳的创新疗 法。" 格隆汇12月29日丨创胜集团-B(06628.HK)宣布，已与全球生物制药开发与生产企业，台康生技股份有限 公司("EirGenix")(TWSE: 6589)达成战略合作与非独占技术许可协议。根据协议，公司将向EirGenix授予 高度一体化连续流生物工艺制造(HiCB)平台的非独占许可，涵盖高产的连续灌流上游工艺与集成的混合 连续下游纯化技术，并提供完整的工艺文档、核心工艺技术与经验及法规支持服务。公司将获得一笔可 观的前期付款及里程碑付款，并可就许可技术的商业化应用收取未来相关的特许权使用费，这充分体现 了双方通过此次合作共同创造长期价值的一致预期。 HiCB平台旨在实现更高的工艺效率、优化工艺控制和产品一致性，与传统流加(f ...

Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6628） 自願公告 創勝集團宣佈達成一項戰略合作與非獨佔技術許可協議， 推進生物藥的一體化連續流生產，提升可負擔生物藥的全球可及性 本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 本公司董事會（「董事會」）欣然宣佈，已與全球生物製藥開發與生產企業，台康生 技股份有限公司（「EirGenix」）(TWSE: 6589)達成戰略合作與非獨佔技術許可協 議。 根據協議，公司將向EirGenix授予高度一體化連續流生物工藝製造(HiCB)平台的 非獨佔許可，涵蓋高產的連續灌流上游工藝與集成的混合連續下游純化技術，並 提供完整 ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团（06628）1万股，每股作价 2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 责任编辑：卢昱君 香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团（06628）1万股，每股作价 2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 责任编辑：卢昱君 ...

香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团(06628)1万股，每股作价2.1435 港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为8.4%。 ...

智通财经APP获悉，香港联交所最新数据显示，12月18日，董事会主席钱雪明增持创胜集团(06628)1万 股，每股作价2.1435港元，总金额约为2.14万港元。增持后最新持股数目为3803万股，持股比例为 8.4%。 ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Insights - The updated efficacy analysis of osemitamab in combination with nivolumab and CAPOX shows promising results in patients with advanced gastric/gastroesophageal junction cancer, particularly those with higher CLDN18.2 expression [1][2][4] Efficacy Analysis - In a cohort of 26 patients with CLDN18.2 expression ≥40%, the median progression-free survival (PFS) was 16.6 months, with an overall response rate (ORR) of 68% and a median duration of response (DoR) of 18 months at a median follow-up of 25.8 months [2] - Better PFS outcomes were observed in patients with higher CLDN18.2 expression compared to lower expressors, indicating consistent treatment benefits across different PD-L1 expression subgroups [2] Safety Profile - The safety profile of the osemitamab combination regimen is consistent with previous presentations, indicating it is well tolerated [3] Expert Commentary - Clinical experts highlight the significance of the consistent benefits across PD-L1 subgroups, suggesting that the osemitamab regimen may provide meaningful improvements for a broad patient population with advanced G/GEJ cancer [4] - The ongoing strength of clinical signals reinforces the potential of osemitamab to offer effective treatment options for patients [4] Product Information - Osemitamab is a high-affinity humanized anti-CLDN18.2 monoclonal antibody that exhibits enhanced antibody-dependent cellular cytotoxicity (ADCC) and has shown potent anti-tumor activities in preclinical models [5] - It has received Orphan Drug Designation in the U.S. for treating gastric or gastroesophageal junction and pancreatic cancer [5] Company Overview - Transcenta Therapeutics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics, with integrated capabilities in discovery, research, development, and manufacturing [6][7] - The company has established a global presence with facilities in Suzhou and Hangzhou, and clinical development centers in China, the U.S., and Europe [7]

Core Insights - The company announced promising clinical results for osemitamab in combination with nivolumab and CAPOX as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma, presented at the ESMO Asia Congress 2025 [1][2] Group 1: Clinical Trial Results - The updated efficacy analysis from the TranStar102 trial showed a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and PD-L1 CPS known [1] - The median duration of response (mDoR) was reported at 18 months, indicating significant clinical benefits from the treatment [1] - Higher CLDN18.2 expression patients demonstrated better PFS regardless of PD-L1 expression levels, suggesting consistent potential therapeutic benefits [1] Group 2: Safety and Clinical Benefit - The safety profile of osemitamab was consistent with previously reported data from the ASCO 2025 conference, indicating good safety and tolerability [2] - The principal investigator highlighted the consistent clinical benefits across different PD-L1 subgroups, suggesting the treatment could provide significant improvements for advanced gastric or gastroesophageal junction adenocarcinoma patients [2] - The global clinical development executive vice president of the company expressed optimism about the strong clinical benefit signals and the potential of osemitamab to offer substantial benefits to patients in need of more effective treatment options [2]

Core Insights - The study results presented at the ESMO Asia Congress 2025 indicate that the combination therapy of osemitamab with nivolumab and CAPOX shows promising clinical benefits for patients with advanced gastric or gastroesophageal junction adenocarcinoma [1][2] Group 1: Clinical Efficacy - The updated efficacy analysis from the TranStar102 trial shows a median progression-free survival (mPFS) of 16.6 months and an objective response rate (ORR) of 68% among 26 patients with CLDN18.2 expression ≥40% and known PD-L1 CPS [1] - The median duration of response (mDoR) is reported to be 18 months, indicating sustained efficacy of the treatment [1] - Higher CLDN18.2 expression correlates with better PFS outcomes regardless of PD-L1 expression levels, suggesting consistent therapeutic benefits across different patient subgroups [1] Group 2: Safety and Tolerability - The safety profile of the combination therapy remains consistent with previously reported data, indicating good tolerability and safety [1][2] - The treatment is expected to provide significant clinical benefits to patients who urgently need more effective treatment options for advanced gastric or gastroesophageal junction adenocarcinoma [2]

新分析结果进一步印证了osemitamab三联疗法所展现的令人鼓舞的临床获益。经过25.8个月的中位随访 观察，在26例CLDN18.2表达≥40%、≥2 + 且PD-L1 CPS 已知的患者中，中位无进展生存期(mPFS)达到 16.6个月，客观缓解率(ORR)为68%，中位缓解持续时间(mDoR)为18个月。值得关注的是，在PD-L1 CPS<1和≥1两个亚组中，CLDN18.2较高表达患者的PFS均优于较低表达患者，这表明 osemitamab的潜 在治疗获益不受PD-L1表达水平影响，具有一致性。 "探索性疗效分析持续表明，osemitamab联合标准治疗方案具有良好的临床获益，" 北京大学肿瘤医院消 化肿瘤内科及I期临床试验病区主任，本次研究的主要研究者沈琳教授表示，"不同PD-L1亚组患者的获 益一致性尤为值得关注，这表明该治疗方案有望为广大晚期胃或胃食管结合部腺癌患者带来具有临床意 义的获益改善。" 智通财经APP讯，创胜集团-B(06628)发布公告，公司董事会欣然宣布，osemitamab联合纳武利尤单抗与 CAPOX作为胃或胃食管结合部腺癌(TranStar102)一线治疗的I/II期临床 ...